Melatonin not found to improve fatigue in patients with advanced cancer
the ONA take:
According to a new study published online ahead of print in the journal Cancer, researchers at Bispebjerg Hospital in Copenhagen, Denmark, have found use of oral melatonin at a dose of 20 mg was not associated with improvement in fatigue or other symptoms in patients with advanced cancer.
For the study, researchers sought to assess the effect of melatonin on fatigue and other symptoms in patients with advanced cancer. Researchers enrolled 72 patients with stage IV cancer who reported significant fatigue and randomly assigned them to receive 1 week of melatonin 20 mg or placebo orally each night. Patients then crossed over and received the opposite treatment for 1 week.
Of those, 50 patients completed the study and 44 were 100% compliant with the interventions. Results showed no difference in physical fatigue or other quality of life measures between melatonin and placebo.
Oral melatonin was not associated with improvement in fatigue or other symptoms in patients with advanced cancer.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|